Literature DB >> 29699128

Pregnancy despite ovarian insufficiency in a patient with breast cancer.

Erica B Mahany1, Dawn L Hershman2, Mark V Sauer1, Janet M Choi1.   

Abstract

Future fertility is a concern for many young breast cancer survivors. Secondary amenorrhea occurs frequently during or soon after oncologic treatment. Return of menstruation and serum biomarkers are not absolute predictors of future fertility. We report a case of a 28 year old gravida 0 with recurrent Stage IIB invasive ductal breast carcinoma who managed to conceive twice despite showing clinical and biochemical signs of decreased ovarian reserve following treatment with chemotherapy and radiation. This case illustrates the potential for fertility in a patient with breast cancer despite chemotherapy-related amenorrhea and undetectable anti-Müllerian hormone levels. It exemplifies the imprecise nature of all clinical tests used to predict future fertility in breast cancer patients post-treatment. It should remind all providers to be careful in basing recommendations for childbearing on these surrogate endpoints.

Entities:  

Keywords:  Breast neoplasms; Chemoradiotherapy; Fertility; Ovarian function tests; Pregnancy

Year:  2012        PMID: 29699128      PMCID: PMC5904670          DOI: 10.1007/s12522-012-0133-x

Source DB:  PubMed          Journal:  Reprod Med Biol        ISSN: 1445-5781


  19 in total

Review 1.  Fertility preservation in young women undergoing breast cancer therapy.

Authors:  Murat Sonmezer; Kutluk Oktay
Journal:  Oncologist       Date:  2006-05

Review 2.  Subsequent pregnancy after breast cancer.

Authors:  F Peccatori; S Cinieri; L Orlando; G Bellettini
Journal:  Recent Results Cancer Res       Date:  2008

3.  Changes in markers of ovarian reserve and endocrine function in young women with breast cancer undergoing adjuvant chemotherapy.

Authors:  Bo Yu; Nataki Douglas; Michel J Ferin; Gary S Nakhuda; Katherine Crew; Rogerio A Lobo; Dawn L Hershman
Journal:  Cancer       Date:  2010-05-01       Impact factor: 6.860

4.  Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation.

Authors:  Kutluk Oktay; Erkan Buyuk; Natalie Libertella; Munire Akar; Zev Rosenwaks
Journal:  J Clin Oncol       Date:  2005-04-11       Impact factor: 44.544

5.  Effect of childbirth after treatment on long-term survival from breast cancer.

Authors:  H M Verkooijen; G H Lim; K Czene; V Bhalla; K Y Chow; K P L Yap; K S Chia; M Hartman
Journal:  Br J Surg       Date:  2010-08       Impact factor: 6.939

6.  Childbearing and survival after breast carcinoma in young women.

Authors:  Beth A Mueller; Michael S Simon; Dennis Deapen; Aruna Kamineni; Kathleen E Malone; Janet R Daling
Journal:  Cancer       Date:  2003-09-15       Impact factor: 6.860

7.  Survival of breast cancer patients after subsequent term pregnancy: "healthy mother effect".

Authors:  R Sankila; S Heinävaara; T Hakulinen
Journal:  Am J Obstet Gynecol       Date:  1994-03       Impact factor: 8.661

8.  Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study.

Authors:  Jeanne A Petrek; Michelle J Naughton; L Douglas Case; Electra D Paskett; Elizabeth Z Naftalis; S Eva Singletary; Paniti Sukumvanich
Journal:  J Clin Oncol       Date:  2006-02-13       Impact factor: 44.544

9.  Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors.

Authors:  H Irene Su; Mary D Sammel; Jamie Green; Luke Velders; Corrie Stankiewicz; Jennifer Matro; Ellen W Freeman; Clarisa R Gracia; Angela DeMichele
Journal:  Cancer       Date:  2010-02-01       Impact factor: 6.860

10.  The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer.

Authors:  R A Anderson; A P N Themmen; A Al-Qahtani; N P Groome; D A Cameron
Journal:  Hum Reprod       Date:  2006-07-04       Impact factor: 6.918

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.